Bevacizumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer
Conditions
- Primary Peritoneal Cavity Cancer
- Recurrent Ovarian Epithelial Cancer
- Stage IV Ovarian Epithelial Cancer
Interventions
- BIOLOGICAL: bevacizumab
- OTHER: laboratory biomarker analysis
Sponsor
National Cancer Institute (NCI)
Collaborators